GEMINA LABS ANNOUNCES LISTING ON THE CANADIAN SECURITIES EXCHANGE

August 10, 2021

GEMINA LABORATORIES LTD. 

News Release 

August 10, 2021 

GEMINA LABS ANNOUNCES LISTING ON THE CANADIAN SECURITIES EXCHANGE 

August 10, 2021, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (the “Company” or  “Gemina”) is pleased to announce that the common shares of the Company have begun trading on the  Canadian Securities Exchange (the “CSE”) at the open of trading on August 10, 2021 under the trading  symbol “GLAB”. 

Gemina Labs is a biosensor and diagnostic company developing next generation health and wellness tests  using our novel transformative patented biochemistry, which has demonstrated very significant  improvements (up to 10 times better limit of detection) in test performance in laboratory settings. Led by  a globally proven team with a track record of success, Gemina is developing highly accurate tests that not  only produce results quickly (within 5 – 10 minutes) but are both affordable and convenient for consumers  and medical practitioners alike. Our approach is to deliver testing at the point of need and to democratize  diagnostic testing. We are addressing a wide range of pathogens that affect both human and animal health  and wellness. Our development pipeline includes platforms for the rapid testing of COVID-19, Influenza  and a variety of other viruses and conditions. 

In conjunction with the public listing, the Company has closed its non-brokered private placement of  $2,406,500 sold at an offering price of $0.30 per unit. Each unit consists of one common share in the  capital of the Company and one half of one common share purchase-warrant. Each warrant entitles the  holder to acquire one additional Common Share of the Company at an exercise price of $0.45 at any time  within three years from the closing date of the private placement. The Company has raised a total of  $4,271,500 to date, inclusive of $990,000 of non-dilutive funding received from the Federal Digital  Supercluster and partners. 

Additional information on the Company can be found in the Company’s final prospectus dated July 28,  2021, as filed under the Company’s profile on SEDAR at www.sedar.com. 

On Behalf of the Board of Directors 

John Davies 

CEO 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  biochemistry that powers next-generation testing platforms for a wide range of pathogens that affect  both humans and animal health and wellness. Our technology drives testing platforms that are fast, affordable, and accurate, and are easily self-administered. Our development pipeline includes platforms  for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can  be found at www.geminalabs.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and  statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

James Tansey 

Telephone: 604-562-4546 

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.